Vendor Intelligence Report: Suaway Lab Research

Executive summary

Across 39 Finnrick lab tests, Suaway Lab Research posts a 62% overall pass rate: 24 pass and 15 fail. The record is not uniformly weak, but it is sharply uneven. GHK-Cu and Ipamorelin are the relative bright spots, while CJC-1295 and Retatrutide sit on the warning side of the catalog; the full report breaks out every product and shows where ratings change under stricter grading.

Suaway presents as a Luxembourg-facing Selkis Group research-materials brand, but the supportable footprint is more complicated. Italian-language archive evidence, an Italian commercial registry trail, a Delaware LLC layer, and the Luxembourg office address do not resolve into a verified EU peptide synthesis laboratory. The strongest operating-entity signal is a small Italian zero-employee wholesale company, while the Delaware record adds ownership opacity rather than clarity.

The manufacturing story is the report’s central buyer-risk issue. Suaway has claimed EU peptide-production capability, yet an archived 2025 site footer placed a Chinese peptide manufacturer inside the Suaway/Selkis corporate presentation. That does not prove the products are fake; it shifts buyer diligence away from simple COA presence and toward origin, lot controls, sterile handling, and safety testing beyond identity and purity.

Suaway’s MZ Biolabs COA examples are useful for identity and purity, but the report documents the missing injectable-safety coverage: sterility, endotoxin, heavy metals, and pH. The reputation layer also needs context: a high Trustpilot score sits beside a review-discount program and a public response pressuring a one-star reviewer to revise upward.

Inside the full report:

• Per-product pass/fail analysis, rating trajectories, and methodology-divergence charts for all 8 tested products
• Corporate entity trail across Italy, Delaware, and Luxembourg, including excluded Selkis false leads
• Wayback evidence for the 2016 Italian site, 2025 outage, and archived Selkis/Suaway/Stark/Omizzur footer
• COA coverage-gap analysis comparing identity/purity testing with missing injectable-safety tests
• Trustpilot review-integrity review, including incentive and negative-review handling artifacts
• Payment, shipping, infrastructure, risk matrix, identifiers, open leads, and re-verification targets

Risk assessment

• Misrepresented corporate identity and ownership-opacity risk — high: Public site foregrounds Luxembourg/Selkis Group while records indicate Selkis S.r.l. in Italy, Selkis LLC in Delaware, and nominee-agent ownership opacity.
• Manufacturing-origin and supplier-opacity risk — high: Suaway claims EU peptide-lab production, but an August 2025 archive linked the operation to Omizzur Biotech, a Chinese peptide manufacturer; no Selkis lab facility was verified.
• Missing injectable-safety testing — high: Published MZ Biolabs COAs cover identity/purity and explicitly exclude sterility, endotoxins, heavy metals and pH for injectable research products.
• Product-specific failure risk — high: Finnrick testing is fail-heavy for CJC-1295 (0/5 pass), Retatrutide (1/5 pass) and Tirzepatide (2/5 pass); Semaglutide is mixed at 3/5 pass.
• Review-integrity risk — high: Trustpilot reputation is weakened by a 5% review incentive and a documented response pressing a 1-star reviewer to change to 4–5 stars.
• Regulatory-alignment risk — high: The best-supported Italian entity is registered under ATECO 46.38.9 wholesale food, and no EU GMP/pharmaceutical/chemical operating registration was found.
• Payment and delivery recourse risk — medium: Bitcoin, bank wire and a no-refund/no-reship policy once a package leaves Suaway shift customs, seizure and delivery loss to the buyer.
• Operational-continuity risk — medium: A 3–4 month 2025 outage, zero-employee Italian registry record and modest 2024 revenue indicate a fragile micro-operator model.